Last reviewed 2026-04-23 · How we verify

Placebo for AG-221

This is a placebo control with no active pharmacological mechanism.

This is a placebo control with no active pharmacological mechanism. Used for Control arm in phase 3 trial for acute myeloid leukemia (AML) with IDH2 mutations (AG-221 indication).

At a glance

Mechanism of action

As a placebo, this product contains no active pharmaceutical ingredient and produces no direct molecular or therapeutic effect. It is used as a control arm in the phase 3 trial of AG-221 to establish efficacy and safety of the active drug through comparison against an inert comparator.

Approved indications

• Control arm in phase 3 trial for acute myeloid leukemia (AML) with IDH2 mutations (AG-221 indication)

Common side effects

No common side effects on file.

Key clinical trials

• MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
• A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Placebo for AG-221 CI brief — competitive landscape report
• Placebo for AG-221 updates RSS · CI watch RSS
• Stichting Hemato-Oncologie voor Volwassenen Nederland portfolio CI